Screener
QuidelOrtho Corporation QDEL JPAC — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by QuidelOrtho Corporation in its filing.
Tagged under the XBRL concept qdel:SegmentInformationResearchAndDevelopmentExpense.
The source filing: QuidelOrtho Corporation’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0001906324-26-000033
| (In millions) | North America | EMEA | China | JPAC | Latin America | Total |
|---|---|---|---|---|---|---|
| Less (1): | ||||||
| Cost of sales, excluding amortization of intangibles | 116.7 | 44.3 | 28.8 | 43.3 | 38.3 | 271.4 |
| Selling, marketing and administrative | 40.7 | 23.9 | 9.5 | 12.3 | 13.2 | 99.6 |
| Research and development | 0.4 | 0.1 | 0.6 | 0.3 | 0.6 | 2.0 |
| Other expense, net | — | 0.8 | (1.4) | 0.1 | (1.6) | (2.1) |
| Total segment Adjusted EBITDA | $169.6 | $22.1 | $30.3 | $18.3 | $19.7 | 260.0 |
| Reconciliation of segment Adjusted EBITDA | ||||||
| Corporate (2) | (130.7) |
Item 1. Financial Statements (unaudited)
FAQ
- What is QuidelOrtho Corporation's JPAC — R&D?
- QuidelOrtho Corporation (QDEL) reported JPAC — R&D of $300K in Q2 2026.
- How has QuidelOrtho Corporation's JPAC — R&D changed year-over-year?
- QuidelOrtho Corporation's JPAC — R&D decreased by 25.0% year-over-year, from $400K to $300K.
- What does JPAC — R&D mean?
- Refers to the expenditures dedicated to the innovation, design, and clinical validation of new diagnostic technologies within the JPAC segment. This investment is critical for maintaining long-term competitiveness and expanding the segment's product portfolio.
Ask your AI about QuidelOrtho Corporation's jpac — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude